QUOTIENT Trademark

Trademark Overview

On Monday, November 20, 2023, a trademark application was filed for QUOTIENT with the United States Patent and Trademark Office. The USPTO has given the QUOTIENT trademark a serial number of 98278615. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Thursday, March 21, 2024. This trademark is owned by Quotient Therapeutics, Inc.. The QUOTIENT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceutical for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, d...
quotient

General Information

Serial Number98278615
Word MarkQUOTIENT
Filing DateMonday, November 20, 2023
Status653 - SUSPENSION LETTER - MAILED
Status DateThursday, March 21, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; therapeutic pharmaceutical for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical compositions comprised of small molecules for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, DNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases; pharmaceutical preparations, namely, RNA therapeutics for the treatment and prevention of cancer, cardiovascular diseases and disorders, respiratory diseases and disorders, gastrointestinal diseases and disorders, genetic and genomic diseases and disorders, immunological diseases and disorders, metabolic diseases and disorders, endocrine diseases and disorders, kidney diseases and disorders, dermatological diseases and disorders, reproductive diseases and disorders, urological diseases and disorders, allergies, bone diseases and disorders, diseases and disorders of the musculo-skeletal and genitourinary systems, and viruses and infectious diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 3, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameQuotient Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Thursday, November 23, 2023NEW APPLICATION ENTERED
Monday, February 26, 2024NON-FINAL ACTION WRITTEN
Monday, February 26, 2024NON-FINAL ACTION E-MAILED
Monday, February 26, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, March 19, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 3, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 20, 2024ASSIGNED TO EXAMINER
Tuesday, March 19, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, March 19, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, March 21, 2024SUSPENSION LETTER WRITTEN
Thursday, March 21, 2024LETTER OF SUSPENSION E-MAILED
Thursday, March 21, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

Related Keywords

quotient diseases disorders genetic genomic immunological kidney endocrine pharmaceutical gastrointestinal metabolic